Navigation Links
MMR Vaccine Immunizations Rates Are On The Rise

National Health Service has conducted a study and found that the rates have increased among those who take the MMR vaccine. //

More parents are getting their children immunized with the three-in-one MMR jab in Scotland. But the rates are still well below the Scottish Executive's target level of 95% by the age of two. But there was a 0.7% increase in the rates of immunization. The drop was due to the vaccines association with the childhood autism disease.

A small-scale study published in The Lancet in 1998 by Dr Andrew Wakefield suggested a link to autism. But later on a major Medical Research Council study of more than 4,000 children concluded in September 2004 that three-in-one injection, against measles, mumps and rubella, was not linked to autism.

Health officials have said 95% of children need to be immunized to ensure herd immunity and to prevent outbreaks of measles, mumps or rubella. The vaccination rates against other childhood diseases have remained well above target levels. According to the figures, uptake rates at the age of two for diphtheria, tetanus, polio and three other diseases have remained relatively stable at 96-97%.

Tory health spokeswoman Nanette Milne said that the single vaccine for these diseases was very costly and could be afforded by the elite community. She said that it was not appropriate and the health minister would find a solution to this kind of a problem.

Health experts have said there was no evidence that single vaccines were safer for children than MMR. A Scottish Executive spokeswoman said that the MMR vaccine is the safest, most effective way to protect all children against the risks of measles, mumps and rubella.


'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
(Date:8/29/2008)... CE Mark Opens Market to More Than 30 European ...a Medical, Inc. announced today,that it has succes...or ISO,13485 and the Medical Device Directive (for...use of the coveted CE Mark -- or Conformite Europe...System. This expands Hoana,s,patient safety reach ...
(Date:8/29/2008)... Allsup explains financial impl...ng calculators available to people with disabiliti...ocus) August 29, 2008 -- Deciding how to move forw... a personal matter, but it,s important that indivi...inancial options, according to http://www.allsup....
(Date:8/28/2008)... Revenues increase 138% versus Q2 2007 - Nine n... 28 /PRNewswire-FirstCall/ - CRH Medical Corporati...or the three and six months,ended June 30, 2008 (a...ee,months ended June 30, 2008 increased 138% to $1...in 2007. Revenue for the six months ended June,30,...
(Date:8/28/2008)...is verbal, financial and physical, especially for ...ug. 28 (HealthDay News) -- A new study says that 1...from various forms of abuse. , The University ...erbal abuse (9 percent), being taken advantage of ... percent). The team also found that seniors with p...
Breaking Medicine News(10 mins):Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 2Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 3Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 4Health News:Social Security Disability Can Be Key to Financial Future 2Health News:Social Security Disability Can Be Key to Financial Future 3Health News:Social Security Disability Can Be Key to Financial Future 4Health News:Social Security Disability Can Be Key to Financial Future 5Health News:Social Security Disability Can Be Key to Financial Future 6Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:13% of Seniors Report Being Mistreated 2
...y published in the May issue of The American Journ...portant role in males as well. Low levels of the f...ure in men, the study found. Those who had low lev...d the greatest risk. The study was conducted by S...
...cancer in women has occurred because of two common...edy from a prevalent chemotherapy medication. Carb...nd lung cancers, is getting known for its success ...tish scientists have conducted a research on mice ...
... anxiety disorder that develops after exposure to ...rding to a study it was found that Vietnam combat ...) //when compared with their non-combat exposed, i... suggests that these deficits are not acquired by ...
...rst partial face transplant patient reports great ...done 5 months back//. Isabelle Dinoire (dee-NWAHR...are more healed and she's recovered total feeling ... two has said she was under the influence of drugs...
Other Medicine News:Health News:Hip Fracture Risk Increases In Men Having Low Estrogen Levels 2Health News:Brain Abnormalities Raise the Risk of PTSD 2
(Date:8/27/2008)...prednisone arm demonstrated a, significant surviv...se -, CAMBRIDGE, Mass., Aug. 27 /- M...nced the publication of results from the 682,patie...eek,s edition of the,New England Journal of Medici...fit and a 30 percent complete remission (CR) rate ...
(Date:8/27/2008)...al, expected by mid-2009 - - Data from second Pha...CKVILLE, Md., Aug. 27 /- Hu...nnounced it has completed enrollment,and initial d... 3,randomized clinical trials of LymphoStat-B(R) (...erythematosus (SLE). Belimumab is being developed ...
(Date:8/26/2008)...mafore Pharmaceuticals Inc.,presented data at the ...es,in Cancer in Washington, D.C., announcing the d... that demonstrate significant anticancer,activity ...molecular scaffold has been developed using,comput...3 kinase inhibitors,as well as isoform-selective s...
(Date:8/26/2008)...FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today a...,from the CUSTOM II trial was published in the mos...ntervention. The lead author of the article was,Dr...nter Utrecht, Utrecht,The Netherlands on behalf o...es across Europe., The one-year CUSTOM II trial, ...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Older Americans are more socially engaged than many people may think 16988 1Older Americans are more socially engaged than many people may think 16988 2Older Americans are more socially engaged than many people may think 16988 3Is there anybody out there 3F 2916 1Is there anybody out there 3F 2916 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 155 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 3MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 1MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 2
...of Peregrine,s,Unique Selective Anti-VEGF Antibodi...l Cancer Models, TUSTIN, Calif., April 20, 2007 /P... Inc. , a clinical stage,biopharmaceutical company... treatment of cancer and hepatitis C virus infecti... presented at the recent,Centennial Annual Meeting...
...Rx Corporation,(NASDAQ:CYTR) today announced that ...clusively licensed to its majority-owned,subsidiar...,published in the April 2007 issue of peer-reviewe...hnology was developed by RXi,Co-founder, Scientifi...setts Medical School (UMMS) Professor of Biochemis...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: